German Red Cross Blood Service Baden-Wuerttemberg-Hesse and the Institute for Transfusion Medicine and Immunohematology, Goethe-University, Frankfurt, Germany.
Transfusion. 2012 May;52(5):1137-45. doi: 10.1111/j.1537-2995.2011.03414.x. Epub 2011 Nov 2.
Granulocyte-colony-stimulating factor-mobilized peripheral blood stem cells, collected by white blood cell apheresis, are used for more than 80% of allogeneic and most autologous hematopoietic stem cell transplantations. Optimal donor and recipient outcomes require maximized stem cell collection efficiency and minimized non-target cell contamination. Therefore, improved apheresis technology is desirable. The safety and feasibility of apheresis collections with the novel, electronics-assisted apheresis system Spectra Optia v.5.0 (CaridianBCT) were recently demonstrated. An unpublished optimization trial had furthermore determined that different settings than manufacturer-installed default might result in improved apheresis yields.
The first prospective comparison of allogeneic peripheral blood stem cell apheresis with the Spectra Optia versus the COBE Spectra (CaridianBCT) mononuclear cell (MNC) in a routine clinical setting is reported here; "optimized" machine settings were used. Assessed variables included collection efficiency, product characteristics, donor outcomes, and frequency of operator interventions. Outcomes were additionally compared with historical data from the Spectra Optia in default mode.
The mean CD34+ cell collection efficiency CE1 was 7.9% greater with the Spectra Optia than with the COBE Spectra MNC. Variability of outcomes was equally great. Reduced platelet (PLT) attrition necessitated 90% fewer autologous PLT reinfusions. Spectra Optia products contained 50% fewer red blood cells, but 50% more granulocytic lineage cells. Less operator input was required, although 26% of Spectra Optia apheresis procedures required triggering of the first chamber flush. Apheresis yield and collection efficiency were also markedly greater than in default-mode Spectra Optia collections.
Using optimized machine settings, peripheral blood stem cell apheresis outcomes with the automated apheresis system Spectra Optia exceed results with the COBE Spectra MNC or the Spectra Optia in the default mode.
粒细胞集落刺激因子动员的外周血造血干细胞通过白细胞单采术采集,用于 80%以上的异基因和大多数自体造血干细胞移植。最佳的供者和受者结果需要最大限度地提高干细胞采集效率,最小化非靶细胞污染。因此,需要改进的单采技术。新型电子辅助单采系统 Spectra Optia v.5.0(CaridianBCT)的安全性和可行性最近得到了证实。一项未发表的优化试验还确定,与制造商安装的默认设置不同的设置可能会导致更好的单采效果。
本研究首次在常规临床环境中对同种异体外周血造血干细胞采集进行前瞻性比较,比较 Spectra Optia 与 COBE Spectra(CaridianBCT)单核细胞(MNC)的单采,使用“优化”机器设置。评估的变量包括采集效率、产品特性、供者结局和操作人员干预的频率。结果还与 Spectra Optia 默认模式下的历史数据进行了比较。
与 COBE Spectra MNC 相比,Spectra Optia 的 CD34+细胞采集效率 CE1 平均提高了 7.9%。结果的变异性同样很大。血小板(PLT)损耗减少,需要的自体 PLT 再输注减少了 90%。Spectra Optia 产品中的红细胞减少了 50%,但粒细胞系细胞增加了 50%。需要的操作人员输入更少,尽管 Spectra Optia 单采程序中有 26%需要触发第一个腔室冲洗。Spectra Optia 的单采产率和采集效率也明显高于默认模式下的 Spectra Optia 采集。
使用优化的机器设置,自动化单采系统 Spectra Optia 的外周血造血干细胞单采结果优于 COBE Spectra MNC 或默认模式下的 Spectra Optia。